Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-334543, EGFR/ErbB2 inhibitor · 5 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARRY-334543 + gemcitabine | EXPERIMENTAL | - |
| ARRY-334543 + docetaxel + prophylactic growth factors | EXPERIMENTAL | - |
| ARRY-334543 + capecitabine | EXPERIMENTAL | - |
| ARRY-334543 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-334543, EGFR/ErbB2 inhibitor; oral | DRUG | multiple dose, escalating |
| Gemcitabine, nucleoside analogue; intravenous | DRUG | multiple dose, single schedule |
| Docetaxel, mitotic inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Prophylactic growth factors; subcutaneous | DRUG | standard of care |
| Capecitabine, 5-fluorouracil prodrug; oral | DRUG | multiple dose, single schedule |
Key Inclusion Criteria (Part 1): * Histologically or cytologically confirmed diagnosis of a solid tumor suitable for treatment with gemcitabine. * No more than 3 prior anticancer regimens for advanced disease. * Measurable or evaluable, nonmeasurable disease. * Eastern Cooperative Oncology Group (E...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | Durvalumab |
| Nanobiotix SA Sponsored ADR | NBTX | 1 | PHASE1 | NBTXR3 |
| Olema Pharmaceuticals, Inc. | OLMA | 1 | PHASE1 | OP-3136, Palazestrant |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
| Pfizer Inc. | PFE | 1 | N/A | Palbociclib |
ARRY-334543 is an oral small molecule drug being developed by Pfizer for the treatment of advanced cancer. It is an EGFR/ErbB2 inhibitor that has been studied in Phase 1 clinical trials, both as a single agent and in combination with chemotherapy agents, in patients with advanced solid tumors.
ARRY-334543 targets EGFR and ErbB2, also known as HER2. It is an EGFR/ErbB2 inhibitor, meaning it is designed to block signaling through these two receptor tyrosine kinases. The trials for ARRY-334543 were biomarker-selected, enrolling patients based on relevant molecular characteristics.
Pfizer, Inc. is the developer of ARRY-334543. Pfizer trades on the New York Stock Exchange under the ticker PFE. The drug is an oral small molecule EGFR/ErbB2 inhibitor being evaluated in oncology.
ARRY-334543 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All five of its recorded trials are Phase 1 studies, and all five are listed as completed, with no active trials currently reported.
Five Phase 1 trials of ARRY-334543 have been conducted, all completed. These include NCT00862524 with gemcitabine in advanced cancer and pancreatic cancer, NCT00833326 with docetaxel, NCT00710736 with capecitabine, and NCT00637702 as a single agent. Total enrollment across the trials was 203 patients.
Yes. ARRY-334543 and ARRY-334543 oral refer to the same drug. ARRY-334543 is an orally administered small molecule EGFR/ErbB2 inhibitor developed by Pfizer for advanced cancer, so the oral designation describes its route of administration rather than a separate product.